Search
CTTQ Applies for New Indication for Cancer Combination Therapy
2 week ago /
Read about 0 minute
Author：小编
CTTQ has announced the approval of a new marketing indication for its innovative drug combination, consisting of bemocizumab injection and anlotinib hydrochloride capsules. This combination therapy is now indicated for the treatment of advanced or unresectable alveolar soft part sarcoma, marking its sixth approved indication. Alveolar soft part sarcoma is a rare and aggressive soft tissue malignancy, typically affecting adolescents, and is associated with a dismal 5-year survival rate.
-
C114 Communication Network -
Communication Home
7 X 24 Track global technological trends
